Skip to main content

DavidChungMDPhD

Oncology New York, NY

Hematologic Oncology

Adult Bone Marrow Transplant and Cellular Therapy Services; Director, Adult Hematopoietic Stem Cell Transplantation Fellowship and Adult Cancer Immunotherapy Fellowship Programs; Memorial Sloan Kettering Cancer Center

Overview of Dr. Chung

Dr. David Chung is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Georgetown University School of Medicine and has been in practice 16 years. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2001 - 2004
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 2001

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - Present
  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2004 - 2025
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • CT State Medical License
    CT State Medical License 2023 - 2024
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Myeloma Crowd Research Award Myeloma Crowd Foundation, 2018
  • Clinical Investigation Award Experimental Therapeutics Center, MSKCC, 2014
  • Translational New Investigator Award Department of Defense, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
    David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
    David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
    David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma... 
    2021 ASH Annual Meeting - 12/13/2021
  • Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT) Followed By Lenalidomide Maintenanc... 
    2020 Transplantation & Cellular Therapy Meetings, Orlando, FL - 2/2020
  • Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma 
    17th International Myeloma Workshop, Boston, MA - 10/2019
  • Join now to see all

Professional Memberships

Hospital Affiliations